Neurocrine Biosciences, Inc. Announces Appointment Of Malcolm Lloyd-Smith As Chief Regulatory Officer
SAN DIEGO, Oct. 1, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Malcolm Lloyd-Smith has joined the executive management team as Chief Regulatory Officer.
"We are very pleased to welcome Malcolm Lloyd-Smith to the Neurocrine leadership team as our Chief Regulatory Officer," said Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences. "Malcolm brings a wealth of worldwide regulatory experience and pharmaceutical development that is critical to executing our regulatory strategy and facilitating the continued growth in our preclinical and clinical development pipeline."
Prior to joining Neurocrine, Mr. Lloyd-Smith, age 59, served as Senior Vice President, Regulatory Affairs, Quality and Clinical at Cadence Pharmaceuticals, Inc. (acquired by Mallinckrodt plc in April 2014), a pharmaceutical company, since August 2012, prior to which he served as Senior Vice President, Regulatory Affairs and Quality Assurance from August 2008. Mr. Lloyd-Smith served as Vice President and Head of Global Regulatory Affairs for Elan Pharmaceuticals, Inc., a pharmaceutical company, from September 2003 to August 2008, after having served in the United Kingdom as its Vice President, International Regulatory Affairs from March 2002 to August 2003. Previously, Mr. Lloyd-Smith served in various positions of increasing responsibility with DuPont Pharma Ltd. (acquired by Bristol-Myers Squibb Company in 2001), serving as Vice President, Worldwide Regulatory Affairs from 2001 to 2002, as Vice President, Regulatory Affairs Europe from 1999 to 2001, and as Senior Director, Regulatory Affairs Europe from 1994 to 1999. Mr. Lloyd-Smith holds a B.Sc. in pharmacology from the University of Leeds, and a M.Sc. in pharmacological biochemistry from Hatfield Polytechnic.
Neurocrine also announced the grant of an inducement award to Mr. Lloyd-Smith pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules in connection with his employment with Neurocrine. In connection with the employment agreement, Mr. Lloyd-Smith was granted an inducement award consisting of a stock option to purchase 65,000 shares of Neurocrine common stock. The stock option will vest over a period of four years, with 25% vesting on the first anniversary of the grant date and the balance vesting each month over the remaining three years. This award is subject to the terms and conditions of Neurocrine's Inducement Plan. This award is effective on October 1, 2014, the first day of the first calendar month following the commencement of his employment with Neurocrine, and has an exercise price of $15.45, which was the closing price of Neurocrine's common stock on the NASDAQ Global Select Market on that date. The award was granted as an inducement material to Mr. Lloyd-Smith's employment pursuant to Rule 5635(b)(4) of the NASDAQ Listing Rules.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders. The Company's two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc., and a wholly owned vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders. Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.
SOURCE Neurocrine Biosciences, Inc.